Tolerability of Inhaled Hypertonic Saline in Infants With Cystic Fibrosis
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
This is an open-label pilot study of the safety and tolerability of 7% hypertonic saline
inhaled twice daily for 14 days in infants with CF, 12 to 30 months of age.
Phase:
N/A
Details
Lead Sponsor:
CF Therapeutics Development Network Coordinating Center
Collaborators:
Cystic Fibrosis Foundation Cystic Fibrosis Foundation Therapeutics